---
title: Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease
euct_id: 2024-518865-85-00
eudra_ct_number: 2021-005024-37
phase: Phase 4
status: Not yet recruiting
sponsor: Universitair Medisch Centrum Groningen
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-518865-85-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-518865-85-00"
ctis_last_updated: "2026-01-20T02:44:11.976044948"
source: EU Clinical Trials Information System (CTIS)
---
# Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease

**EU CT Number:** [2024-518865-85-00](https://euclinicaltrials.eu/ctis-public/view/2024-518865-85-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Not yet recruiting
- **Sponsor:** Universitair Medisch Centrum Groningen
- **Start Date:** 2021-11-01
- **Completion Date:** 2025-09-30
- **Conditions:** Alzheimers Disease, sporadic Cerebral Amyloid Angiopathy, Parkinson
- **Interventions:** 5-(1-(2-[18F] fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Universitair Medisch Centrum Groningen, Groningen, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Alzheimers Disease; sporadic Cerebral Amyloid Angiopathy; Parkinson
Age groups: adults 18-64, elderly 65+
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-518865-85-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-518865-85-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-518865-85-00*